Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15925864 | 1.00 | BRD4 (0.83) | BRD4 | |
| SCHEMBL30411255 | 0.92 | BRD4 (0.83) | BRD4 | |
| SCHEMBL9282455 | 0.92 | BRD4 (0.83) | BRD4 | |
| SCHEMBL15925858 | 0.91 | BRD4 (0.82) | BRD4 | |
| SCHEMBL18551010 | 0.91 | BRD4 (0.81) | BRD4 | |
| Pelabresib SCHEMBL23289020 | 0.91 | BRD4 (1.00) | BRD4 | |
| Pelabresib SCHEMBL29382955 | 0.91 | BRD4 (1.00) | BRD4 | |
| SCHEMBL15925861 | 0.91 | BRD4 (0.69) | BRD4 | |
| Pelabresib SCHEMBL15926539 | 0.91 | BRD4 (1.00) | BRD4 | |
| Pelabresib SCHEMBL17354054 | 0.90 | BRD4 (0.98) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| WO-2021262731-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2019199816-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2018144649-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | Arvinas, Inc. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-9522920-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8796261-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | BRD4 10/4885 |
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | TP53, TP53BP1, MDM2 | BRD4 1654/4885 |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | NEK1, NEK11, CDK9 | BRD4 12/4885 |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.